Engineered immune cells take aim at hard-to-treat t-cell cancers

NCT ID NCT03690011

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 36 times

Summary

This early-phase trial tests a new treatment for people with T-cell leukemia or lymphoma that has come back or not responded to standard therapy. Doctors take a patient's own T cells, modify them in the lab to recognize and attack cancer cells carrying the CD7 protein, and infuse them back. The main goal is to check safety and find the right dose, while also seeing if the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Texas Children's Hospital
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA T-NON-HODGKIN LYMPHOMA T-NON-HODGKIN LYMPHOMA